Integrating oncolytic viruses in combination cancer immunotherapy
- PMID: 29743717
- DOI: 10.1038/s41577-018-0014-6
Integrating oncolytic viruses in combination cancer immunotherapy
Erratum in
-
Author Correction: Integrating oncolytic viruses in combination cancer immunotherapy.Nat Rev Immunol. 2018 Aug;18(8):536. doi: 10.1038/s41577-018-0031-5. Nat Rev Immunol. 2018. PMID: 29930315
Abstract
Oncolytic viruses can be usefully integrated into tumour immunotherapies, as they target multiple steps within the cancer-immunity cycle. Oncolytic viruses directly lyse tumour cells, leading to the release of soluble antigens, danger signals and type I interferons, which drive antitumour immunity. In addition, some oncolytic viruses can be engineered to express therapeutic genes or can functionally alter tumour-associated endothelial cells, further enhancing T cell recruitment into immune-excluded or immune-deserted tumour microenvironments. Oncolytic viruses can also utilize established tumours as an in situ source of neoantigen vaccination through cross-presentation, resulting in regression of distant, uninfected tumours. These features make oncolytic viruses attractive agents for combination strategies to optimize cancer immunotherapy.
Similar articles
-
The role of oncolytic virus immunotherapies to subvert cancer immune evasion.Future Oncol. 2015;11(4):675-89. doi: 10.2217/fon.14.254. Future Oncol. 2015. PMID: 25686121 Review.
-
Oncolytic viruses and immunity.Curr Opin Immunol. 2018 Apr;51:83-90. doi: 10.1016/j.coi.2018.03.008. Epub 2018 Mar 16. Curr Opin Immunol. 2018. PMID: 29550660 Free PMC article. Review.
-
Combining oncolytic virotherapy and tumour vaccination.Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):143-8. doi: 10.1016/j.cytogfr.2010.02.009. Epub 2010 Mar 11. Cytokine Growth Factor Rev. 2010. PMID: 20226716 Review.
-
Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.J Immunol. 2018 Jan 15;200(2):450-458. doi: 10.4049/jimmunol.1701021. J Immunol. 2018. PMID: 29311387 Review.
-
Oncolytic Immunotherapy for Treatment of Cancer.Adv Exp Med Biol. 2016;909:241-83. doi: 10.1007/978-94-017-7555-7_5. Adv Exp Med Biol. 2016. PMID: 27240460 Review.
Cited by
-
Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma.Mol Ther Oncolytics. 2020 Jun 24;18:171-188. doi: 10.1016/j.omto.2020.06.011. eCollection 2020 Sep 25. Mol Ther Oncolytics. 2020. PMID: 32695875 Free PMC article.
-
Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?Hum Vaccin Immunother. 2021 Oct 3;17(10):3502-3510. doi: 10.1080/21645515.2021.1924521. Epub 2021 Jun 8. Hum Vaccin Immunother. 2021. PMID: 34101538 Free PMC article. Review.
-
Oncolytic Virotherapy and Microenvironment in Multiple Myeloma.Int J Mol Sci. 2021 Feb 24;22(5):2259. doi: 10.3390/ijms22052259. Int J Mol Sci. 2021. PMID: 33668361 Free PMC article. Review.
-
Extracellular vesicles remodel tumor environment for cancer immunotherapy.Mol Cancer. 2023 Dec 13;22(1):203. doi: 10.1186/s12943-023-01898-5. Mol Cancer. 2023. PMID: 38087360 Free PMC article. Review.
-
Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response.Curr Oncol. 2023 Dec 19;31(1):1-23. doi: 10.3390/curroncol31010001. Curr Oncol. 2023. PMID: 38275827 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
